18 results about "Cancer marker" patented technology

The present application relates to the medical technical field, especially to the application of FYB1 gene as a marker in preparation of gastric cancer diagnosis or prognosis judging reagent. The present application research finds that FYB1 gene is highly expressed in gastric cancer tissue and negatively correlated with the prognosis of patients, and can be used as a gastric cancer marker for gastric cancer detection and efficacy evaluation. In addition, FYB1 is positively correlated with the expression of Treg cell marker FOXP3 and co-localized in tissues, suggesting that FYB1 may promote gastric cancer tumor immune escape; the expression of FYB1 gene can significantly inhibit the proliferation, migration and invasion ability of gastric cancer cells, and inhibit tumor growth, indicating that FYB1 gene can be used as a gastric cancer treatment target and play an important role in the treatment of gastric cancer patients.

Provided herein are kits and methods useful for cancer diagnosis, prognosis, research and therapy. In particular, provided herein are methods of diagnosing, prognosing, and / or treating prostate cancer based on expression levels of cancer markers.

Provided herein are kits and methods useful for cancer diagnosis, prognosis, research and therapy. In particular, provided herein are methods of diagnosing, prognosing, and / or treating prostate cancer based on expression levels of cancer markers.

The application provides a plasma exosome mRNA biomarker and application thereof in construction of a gastric cancer diagnosis model, and relates to the technical field of biological medicine.The application first discovers that plasma exosome mRNA MORC3 is significantly enriched in plasma of gastric cancer patients, indicating that the plasma exosome mRNA MORC3 is expected to be used as a biomarker for gastric cancer diagnosis and as a target gene for treatment of gastric cancer.We take the plasma exosome mRNA MORC3 as a target marker to construct a diagnosis model and a corresponding diagnosis system for gastric cancer.The diagnosis model provided by the application shows high sensitivity and specificity in distinguishing gastric cancer patients from healthy people, displays good diagnosis efficiency, and can effectively identify gastric cancer patients, thereby providing an effective auxiliary tool for clinical diagnosis.The application provides a new choice for a molecular marker for gastric cancer diagnosis, overcomes the low sensitivity of existing cancer markers when used for gastric cancer diagnosis, and provides a new method for early screening and diagnosis of gastric cancer.

Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are methods of treating basal-like breast cancer based on expression levels of a panel of cancer markers.

Provided herein are kits and methods useful for cancer screening, diagnosis, research and therapy. In particular, provided herein are methods of screening, diagnosing, and / or treating prostate cancer based on expression levels of cancer markers.

The invention relates to the technical field of biological detection, and provides an integrated electrochemical detection device for stomach cancer postoperative MRD auxiliary detection as well as a preparation method and application of the integrated electrochemical detection device. The core of the device is that a functional nanofiber sensing interface layer and a preset freeze-drying reagent layer are sequentially constructed on a working area of a screen printing electrode (SPE). Wherein the sensing interface layer fixes an anti-CD63 capture antibody through an electrostatic spinning polyacrylic acid (PAA) nanofiber membrane, and is used for efficiently enriching plasma exosomes; and the freeze-drying reagent layer comprises a detection antibody of a targeted gastric cancer marker Claudin18.2, a streptavidin-horse radish peroxidase signal reporting system and a freeze-drying protective agent. According to the invention, the unification of high precision of detection and extremely simplified operation is realized through a unique'mask protection 'process and a'reagent freeze-drying integration' technology. The device has the outstanding advantages of high detection sensitivity, good specificity, convenience in operation, good accuracy and the like.

Recently, aptamers have been considered in cancer diagnosis and treatment applications by binding to various bioreceptor molecules. Given that the p53 protein is responsible for approximately 50% of cancers, its identification is promising, but so far, no aptamer DNA sequence has been designed for the p53 protein and aptamer-based sensor. The purpose of this invention is to develop a nanoparticle-based aptamer sensor and use the p53 bioreceptor for cancer diagnosis with high sensitivity in the shortest time. In this regard, a DNA aptamer-based sensor was used on a glassy carbon electrode coated with gold nanoparticles / graphene oxide / conductive polymer . This sensor was created by the gold nanoparticles / aptamer-toluidine blue enhancer. The results obtained under optimal conditions of electrochemical investigation using amperometry indicated a detection limit of 0.29 picograms / mL in phosphate buffer and 0.341 picograms / mL in human blood plasma and a linear range of 1 to 300 picograms / mL for the sensor. This invention demonstrates the excellent and controllable performance of a modified carbon electrode to create a suitable sensor for detecting the cancer marker p53 protein.

The invention provides a method for detecting a cancer marker miR-155 by using a biosensor for dynamically regulating and controlling Cas12a trans-cleavage activity by utilizing catalytic hairpin assembly mediated transcription pre-crRNA. A transcription template containing a T7 promoter is formed by catalyzing a hairpin assembly (CHA) reaction, so that self-supply of pre-crRNA is realized. Specifically, pre-crRNA and trigger are hybridized to form a compound, after the compound is combined with Cas12a protein, the self-processing function of the pre-crRNA is triggered, and then the cleavage activity of Cas12a is reassembled and activated, so that regulation and control of the Cas12a are realized. A detection signal is amplified in a cascade manner by combining a catalytic hairpin assembly reaction with a T7RNA polymerase mediated signal amplification module, so that high-sensitivity and high-specificity detection of miR-155 is realized, and the detection limit reaches 86 aM. The sensor shows good reliability, low background interference, operability and programmability in a complex sample, and can be applied to detection of miR-155 in tumor cells.

The invention discloses a gastric cancer biomarker ENO3 and a detection reagent thereof, belongs to the technical field of biological medicines, and particularly relates to a detection reagent of a gastric cancer marker. The detection reagent comprises an upstream primer and a downstream primer of a gastric cancer marker, and modified immunomagnetic beads, the gastric cancer marker is enolase 3. The invention finds and verifies that the gastric cancer marker enolase 3 promotes malignant transformation of gastric cancer by promoting glycolysis of gastric cancer cells, activating a WNT / beta-catenin signal channel and up-regulating expression of matrix metalloproteinase at the same time; meanwhile, by optimizing an immunomagnetic bead structure targeting the marker, the capture efficiency of the marker on trace tumor cells in peripheral blood is improved, so that the signal intensity of subsequent marker detection is enhanced, and an important tool is provided for improving the positive detection rate of gastric cancer detection based on the peripheral blood.

A technique for detecting a specific protein that is suitable as a cancer marker with high sensitivity. This technique includes a method for detecting CEACAM1, which involves denaturing CEACAM1 in a CEACAM1-containing specimen to produce a denatured CEACAM1; and detecting CEACAM1 by a sandwich assay using both a capture antibody and a labeled antibody that have an ability to recognize the denatured CEACAM1.

The application provides an immunochemical luminescence kit for detecting a cancer marker HPV18 E7 protein, the kit comprising biotin-labeled antibody 1 and acridinium ester-labeled antibody 2; the antibody 1 is a rabbit-derived monoclonal antibody, comprising a heavy chain and a light chain; the antibody 1 heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO. 1-3; the antibody 1 light chain variable region comprises VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO. 9-11; the antibody 2 is a rabbit-derived monoclonal antibody, comprising a heavy chain and a light chain; the antibody 2 heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO. 17-19; and the antibody 2 light chain variable region comprises VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO. 25-27. The application can improve the test sensitivity, improve the detection rate of weak positive samples, realize accurate quantification of HPV18 E7 protein in cervical exfoliated cells, and the detection method of the application is simple in operation, fully automatic in the detection process, and can greatly improve the detection efficiency.

The invention belongs to the technical field of biological medicine, and discloses a cancer marker and application, and the cancer marker is ICAM1 and a reverse complementary chain ICAM1-AS thereof. Experiments prove that ICAM1 / ICAM1-AS can be specifically bound with an ILF2 / ILF3 protein compound, tumor cell proliferation is affected by regulating and controlling the genome binding capacity of ILF2 / ILF3 and an EIF4E-mediated translation process, and the ICAM1 / ICAM1-AS has remarkable down-regulated expression in tumor tissues such as lung cancer. Based on the characteristics, a reagent for detecting ICAM1 / ICAM1-AS mRNA expression can be used for preparing an early-stage cancer diagnosis or prediction product, a product containing the ILF2 / ILF3 antibody can be used for predicting the cancer immunotherapy effect, and a new technical means and a potential target are provided for early-stage screening and treatment scheme optimization of cancers.

The invention discloses a cancer marker screening method and system combining a co-methylation module and cellular component correlation analysis, and relates to the technical field of bioinformatics, the method comprises the following steps: obtaining DNA methylation sequencing data of a cancer tissue sample group and a control tissue sample group, and preprocessing to generate a methylation matrix; performing differential methylation analysis to obtain differential sites, and forming differential methylation fragments according to an adjacent merging rule; a co-methylation network is constructed based on fragment methylation level correlation, and module characteristic values are obtained through division; and estimating cell components by using the methylation reference spectrum and / or single cell data, screening a target module according to a rule that a module characteristic value is related to a cancer cell ratio and is not related to a non-cancer cell ratio, and outputting a cancer cell specific candidate fragment set. By means of the technical scheme, cell mixing and infiltration interference is inhibited, the specificity and stability of the marker are improved, and cross-queue consistency and typing diagnosis performance are improved.

The present invention provides a method for regulating proliferation of isolated hepatocarcinoma cells. According to an embodiment of the present invention, at least one of HKDC1 expression or protein kinase activity or RBBP5 phosphorylation level is regulated in the hepatocarcinoma cells. According to the method of an embodiment of the present invention, the proliferation rate of the isolated hepatocarcinoma cells can be significantly regulated.

The application provides an immunochemiluminescence kit for detecting a cancer marker HPV16 E7 protein, the kit comprising biotin-labeled antibody 1 and acridinium ester-labeled antibody 2; the antibody 1 is a mouse monoclonal antibody, comprising a heavy chain and a light chain; the amino acid sequence of the antibody 1 heavy chain is shown in SEQ ID NO: 17, and the amino acid sequence of the antibody 1 light chain is shown in SEQ ID NO: 18; the antibody 2 is a rabbit-derived monoclonal antibody, comprising a heavy chain and a light chain; the antibody 2 heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO. 1-3; and the antibody 2 light chain variable region comprises VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO. 9-11. The application can improve test sensitivity, improve the detection rate of weak positive samples, identify early cervical cancer, realize accurate quantification of HPV16 E7 protein in cervical exfoliated cells, and has the advantages of simple operation, automatic detection process and greatly improved detection efficiency.

Fibroblast activation protein a (FAP) is a tumor-specific protein and well characterized for its function in tumorigenicity. However, agents against its enzymatic activity or monoclonal antibodies against its cell surface presence are unsuccessful in clinic for uncharacterized reason. In this disclosure, provided is an anti-FAP siRNA and FAP-silencing oligonucleotides comprising anti-FAP siRNAs linked at both ends to aptamers recognizing cancer markers, in particular aptamers recognizing epithelial cell adhesion molecule (EpCAM).

The application discloses a single-cell ecDNA clone track recognition method, and recognizes potential tumor markers in single-cell ATAC data based on ecDNA clone characteristics. The application can sensitively recognize tumor cells and perform early diagnosis by recognizing cancer markers through ecDNA; the copy number, structure and distribution of ecDNA often have great heterogeneity in tumor cells. Different tumor cell populations may carry different types of ecDNA clones, and the application helps to reveal the evolution track of tumors and the diversity of cell populations thereof; by studying the clone track of ecDNA, the application can reveal the gene structure changes of tumor cell populations in different stages, thereby providing potential markers for early screening and monitoring of cancers.